BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7608273)

  • 1. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas.
    Scheumman GF; Hoang-Vu C; Cetin Y; Gimm O; Behrends J; von Wasielewski R; Georgii A; Birchmeier W; von Zur Mühlen A; Dralle H
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2168-72. PubMed ID: 7608273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-cadherin: a differentiation marker in thyroid malignancies.
    Brabant G; Hoang-Vu C; Cetin Y; Dralle H; Scheumann G; Mölne J; Hansson G; Jansson S; Ericson LE; Nilsson M
    Cancer Res; 1993 Oct; 53(20):4987-93. PubMed ID: 8402689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue.
    Serini G; Trusolino L; Saggiorato E; Cremona O; De Rossi M; Angeli A; Orlandi F; Marchisio PC
    J Natl Cancer Inst; 1996 Apr; 88(7):442-9. PubMed ID: 8618236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology.
    McCaffrey JC
    Laryngoscope; 2006 Jan; 116(1):1-11. PubMed ID: 16481800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
    Furlan JC; Bedard YC; Rosen IB
    J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysadherin: expression and clinical significance in thyroid carcinoma.
    Sato H; Ino Y; Miura A; Abe Y; Sakai H; Ito K; Hirohashi S
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4407-12. PubMed ID: 12970317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome.
    von Wasielewski R; Rhein A; Werner M; Scheumann GF; Dralle H; Pötter E; Brabant G; Georgii A
    Cancer Res; 1997 Jun; 57(12):2501-7. PubMed ID: 9192832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.
    Mitselou A; Ioachim E; Peschos D; Charalabopoulos K; Michael M; Agnantis NJ; Vougiouklakis T
    Exp Oncol; 2007 Mar; 29(1):54-60. PubMed ID: 17431390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Small thyroid carcinomas: biological characteristics, diagnosis and therapy].
    Gemsenjäger E; Schweizer I
    Schweiz Med Wochenschr; 1999 May; 129(18):681-90. PubMed ID: 10407941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
    Gemsenjäger E; Heitz PU; Martina B; Schweizer I
    Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
    Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
    Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
    Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
    Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of e-cadherin in papillary thyroid carcinoma].
    Walgenbach S; Sternheim E; Bittinger F; Görges R; Andreas J; Junginger T
    Chirurg; 1998 Feb; 69(2):186-90. PubMed ID: 9551263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of CK19, vimentin and E-cadherin in differentiated thyroid carcinomas.
    Calangiu CM; Simionescu CE; Stepan AE; Cernea D; Zăvoi RE; Mărgăritescu C
    Rom J Morphol Embryol; 2014; 55(3):919-25. PubMed ID: 25329121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-cadherin gene alterations are rare events in thyroid tumors.
    Soares P; Berx G; van Roy F; Sobrinho-Simões M
    Int J Cancer; 1997 Jan; 70(1):32-8. PubMed ID: 8985087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of E-cadherin expression in thyroid follicular carcinoma.
    Brecelj E; Frković Grazio S; Auersperg M; Bracko M
    Eur J Surg Oncol; 2005 Jun; 31(5):544-8. PubMed ID: 15922891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of insular versus papillary/follicular thyroid carcinoma.
    Falvo L; Catania A; D'Andrea V; Grilli P; D'Ercole C; De Antoni E
    Am Surg; 2004 May; 70(5):461-6. PubMed ID: 15156957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.